Filing Details
Skye Bioscience, Inc. (NASDAQ:SKYE) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:SKYE
Skye Bioscience, Inc. (SKYE) Files Quarterly Report for Q0
Skye Bioscience, Inc. (NASDAQ:SKYE) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
At publication ·
What changed
Skye Bioscience, Inc. (NASDAQ:SKYE) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Skye Bioscience, Inc. filed its quarterly report (Form 10-Q) with the SEC on August 14, 2026, providing unaudited financial statements and management commentary for Q0.
- The company's stock trades at $0.50 per share with a market capitalization of $37.0 million.
- The quarterly report includes updated risk factors and information about changes in business conditions since the last filing, though specific revenue figures were not disclosed in this summary.
Market Context
Skye Bioscience, Inc.'s stock currently trades at $0.50 with a market capitalization of $37.0M.
The 10-Q provides Skye Bioscience, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Skye Bioscience, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SKYE Stock Page
Frequently Asked Questions
Where can I read SKYE's SEC filings?
Browse all filings on our SKYE SEC filings page.
What types of SEC filings does Skye Bioscience, Inc. file?
Public companies like Skye Bioscience, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.